Member Info for chriszzr

Look at the balance sheet !
This will end in tears

500k short reported as closed yesterday
Prior to the anticipated increase in sp

Does anyone else think that these will be the last trades we will ever see below 100 P ?

15-Feb-21 16:29:59 26.90 911 Buy* 26.00 27.00 245.06 O

15-Feb-21 09:02:24 25.75 350,000 Buy* 24.50 25.50 90.13k O

Good post
Monday may turn out to be an interesting day

What is going on here?
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
12-Feb-21 10:17:24 4.2975 232 Buy* 4.20 4.30 9.97 O
12-Feb-21 09:38:05 4.295 23,282 Buy* 4.20 4.30 999.96 O
12-Feb-21 09:30:44 4.299 2,326 Buy* 4.20 4.30 99.99 O

There seems to be a number of large trades going through early this morning, are we finally getting close to the end game?

Form 8.3 - Eurasia Mining plc
Released 15:20:05 11 February 2021

RNS Number : 8005O
BlackRock Group
11 February 2021

FORM 8.3



PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")





1. KEY INFORMATION



(a) Full name of discloser:

BlackRock, Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Eurasia Mining plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:



(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10 February 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No



2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE



If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.



(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)



Class of relevant security:



0.1p ordinary





Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

35,389,840

1.28%

0

0.00%

(2) Cash-settled derivatives:



0

0.00%

408,597

0.01%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00%

0

0.00%



TOTAL:

35,389,840

1.28%

408,597

0.01%



All interests and all short positions should be disclosed.



Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).



(b) Rights to subscribe for new securities (including directors' and other employee options)



Class of relevant security in relation to which subscription right exists:



Details, including nature of the rights concerned and relevant percentages:





3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE



Where there have been dealings in more than one class of relevant securities of the offeror or offeree named i

Is Kentan still on the BB, he usually had a good insight into what was going on

Now that the sp is 1p will we see Eufingest convert their bonds to shares?

The board of Clear Leisure (AIM: CLNow that the sp is 1p will we see Eufingest convert their bonds to shares?
P) is pleased to announce that the Company has entered into a binding agreement with Eufingest SA (“Eufingest”) to convert all Eufingest's outstanding loans plus accrued interest to date, amounting to €3,423,707 (the “Eufingest Loans”) into either the Company’s Zero Coupon Bond or a new, similar bond security (“the Bond”) with a maturity date of 15 December 2022 and a yield to maturity of 1%.

As part of the agreement with Eufingest, the Company will provide a security over any proceeds arising from the Company’s claim against Sipiem (referred to most recently in the Company's announcement of 27 October 2020). It has also been agreed that Eufingest will have the right to convert, at any time, the Bond into new Clear Leisure ordinary shares at a conversion price of 1p per ordinary share.

Eufingest already holds €3m of the Zero Coupon Bond the total face value of which currently in issue is €4.8m.

Eufingest is a substantial shareholder in the Company as defined by the AIM Rules for Companies. The conversion of the Eufingest Loans into the Bond and extension of the repayment date is therefore a related party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. The directors of the Company, having consulted with its nominated adviser, consider that the transaction is fair and reasonable insofar as its shareholders are concerned

Jim
A lot of those holdings are nominee accounts where most pi's shares are held, depending on who you trade with

Does anyone know who took the placing?
Presume a TR1 will be issued at some point

Does this tell us anything?

11-Feb-21 08:21:24 4.875 100,001 Buy* 4.70 4.90 4,875 O

Now who could that be for?

Revenue from COVID-19 activities is expected to be approximately £1.5 million which includes sales from the UK-RTC antibody test, sales of the Mologic ELISA antibody test and development income for work undertaken on behalf of a third party.

RNS Number : 6948O
Omega Diagnostics Group PLC
11 February 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")



Directorate Change



Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect, after a thorough search process that was conducted with the help of Snedden Campbell Ltd. Simon has also become a member of both the Audit Committee and the Remuneration Committee.



Simon has 25 years of Board level experience at both early stage and public businesses within the Diagnostics, Life Science and BioPharma industries. Simon is currently Non-Executive Chairman at AIM listed Fusion Antibodies plc, having previously served as its Chief Executive Officer up until 2011. Simon is also Non-Executive Chairman of C-Major Medical, a private limited company. Simon holds a PhD in in-vivo Diagnostics and an MPhil in Immunology, both from the University of Southampton.



As a result of the appointment, Bill Rhodes has stepped down from his position as Interim Non-Executive Chairman with immediate effect, but he remains as a Non-Executive Director of the Company.



Bill Rhodes said:

"It has been my honour to serve as Interim Chairman for nearly three years now. We have seen Omega gain significant momentum recently as the need for accurate lateral flow diagnostic tests has increased, and I believe Simon is the right individual to support the Company in gaining even greater levels of success."



Colin King, Chief Executive Officer said:

"We very much welcome Simon to the board and look forward to working with him and benefiting from his wide experience. We thank Bill for all his work as our Interim Chairman and look forward to his ongoing contribution as part of our expanded Board."



Simon Douglas, Chairman said:

"I am delighted to be joining Omega at such an exciting time in their development and growth. I look forward to contributing to the continued growth of their core businesses in infectious disease with their lateral flow CD4 and Covid products, together with their Food Intolerance business, a market leader in this sector, both of which have an exciting future."



The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.



The following information is disclosed about Dr. Simon Gordon Douglas, age 62, pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:



Current Directorships / Partnerships:



Fusion Antibodies plc

C-Major Limited (since September 2019)



Previous Directorships / Partnerships (held in the past five years)



Biofortuna Ltd

C-Major Limited (September 2014 until May 2017)



Dr. Douglas does not currently hold any ordina

I wonder how many other large, late trades we shall see tonight?

What reason would they do that for?
Surely it is their own interest for the SP to rise

09-Feb-21 15:16:06 4.902 25,000 Sell* 4.90 5.10 1,226 O
09-Feb-21 15:15:53 4.902 30,000 Sell* 4.90 5.10 1,471 O
09-Feb-21 15:15:39 4.94 30,000 Sell* 4.90 5.10 1,482 O
09-Feb-21 15:03:44 4.90 50,000 Sell* 4.90 5.10 2,450 O
09-Feb-21 15:02:36 4.915 50,000 Sell* 4.90 5.10 2,458 O
09-Feb-21 15:01:59 4.915 50,000 Sell* 4.90 5.10 2,458 O
09-Feb-21 15:01:42 4.94 39,525 Sell* 4.90 5.10 1,953 O
09-Feb-21 15:01:27 4.92 100,000 Sell* 4.90 5.10 4,920 O
09-Feb-21 15:01:05 4.94 100,000 Sell* 4.90 5.10 4,940 O
09-Feb-21 13:54:12 4.975 100,503 Sell* 4.90 5.10 5,000 O

LargeGin

I agree that something is ongoing , the last published accounts showed the BOD had spend £275k on the "Proposed Transaction" and we had the recent update.
Just one thing with the shares held and percentages, other than as shown for Mr Glogowski the other percentages are incorrect as you can see
Still expecting a positive outcome, eventually
Chris